ALS mutations with the FUS gene have been shown to alter the stoichiometry of proteins involved in NMD, including UPF1, highlighting manipulation of this pathway as a potential therapeutic target for FUS-ALS (Kamelgarn et al., 2018). Here, FUS is linked to amyotrophic lateral sclerosis.